Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €3.68 EUR
Change Today -0.12 / -3.16%
Volume 70.9K
TNG On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

transgene sa (TNG) Snapshot

Open
€3.85
Previous Close
€3.80
Day High
€3.85
Day Low
€3.67
52 Week High
07/7/14 - €9.90
52 Week Low
07/2/15 - €3.60
Market Cap
141.8M
Average Volume 10 Days
185.8K
EPS TTM
€-1.26
Shares Outstanding
38.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRANSGENE SA (TNG)

Related News

No related news articles were found.

transgene sa (TNG) Related Businessweek News

No Related Businessweek News Found

transgene sa (TNG) Details

Transgene S.A., a biopharmaceutical company, engages in the research, design, development, and manufacture of therapeutic vaccines and immunotherapeutic products to treat cancers and chronic infectious diseases. Its principal products under Phase II clinical trials include TG4010 for the treatment of metastatic non-small cell lung cancer in combination with chemotherapy; Pexa-Vec primarily for the treatment for liver cancer; TG4001, a therapeutic vaccine for oropharyngeal cancer caused by an infection by the human papilloma virus (HPV); and TG4040 for the treatment of chronic hepatitis C. The company has agreements with Novartis for the development of TG4010 to treat various cancers; Jennerex Biotherapeutics, Inc. for the development and marketing of Pexa-Vec, an oncolytic product; and European Organization for Research and Treatment of Cancer for the development of TG4001 to treat HPV induced head and neck cancers. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene S.A. is a subsidiary of TSGH SAS.

266 Employees
Last Reported Date: 04/29/15
Founded in 1979

transgene sa (TNG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €72.2K
Compensation as of Fiscal Year 2013.

transgene sa (TNG) Key Developments

Transgene Plans to Restructure Manufacturing Operations

Transgene announced that it plans to restructure manufacturing operations and reorganize the biotechnology company's research model. The firm will discontinue manufacturing vector-based immunotherapies at its Illkrich facility near Strasbourg, although it has not offered a firm indication of the precise timescale for this closure. In effect, the company is redirecting its corporate strategy to focus on clinical development. To compensate, the company is expected to rely more heavily on outside drug contractors and collaborations agreements with academic research organizations at an earlier stage of product development as well as partnerships with larger pharmaceutical players. Envisaged financial savings from the reorganization will be reallocated to developing a research and development (R&D) pipeline.

Transgene SA Presents at French Life Science Days conference, Jun-17-2015

Transgene SA Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Transgene SA Presents at CF&B Spring European Midcap Event 2015, Jul-01-2015 through Jul-02-2015

Transgene SA Presents at CF&B Spring European Midcap Event 2015, Jul-01-2015 through Jul-02-2015. Venue: Pullman Paris Tour Eiffel, 18 Avenue de Suffren, Paris, France. Presentation Date & Speakers: Jul-01-2015, CASTELLI Elisabetta, IRO. Jul-02-2015, CASTELLI Elisabetta, IRO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNG:FP €3.68 EUR -0.12

TNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNG.
View Industry Companies
 

Industry Analysis

TNG

Industry Average

Valuation TNG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENE SA, please visit www.transgene.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.